



Favipiravir (FAVI) and Remdesivir DRUG-DRUG INTERACTIONS (DDIs)

FAVIPIRAVIR

Prodrug conversion and antiviral action *may* be inhibited by acyclovir.

Final metabolism *may* be inhibited by cimetidine, tamoxifen, calcium channel blockers, TCAs, and ondansetron

FAVI *may* be a P450 inhibitor and affect diabetes drugs, loop diuretics, and buprenorphine

REMDESIVIR

Inhibits viral replication, now in clinical trials in the US.

In vivo metabolism appears to be chiefly by hydrolase activity, not P450 enzyme system

Few, if any, verified reports of significant P450 DDIs involving remdesivir at this time



FAVI and remdesivir **do not have FDA approval**, so DDI information is incomplete, but DDIs for these drugs appear at present to be fewer than for alternative COVID-19 therapies – but clinicians must remain vigilant.

NOTE: FAVI diminishes acetaminophen metabolism (sulfonation), daily dose of acetaminophen **MUST NOT** exceed 3000 mg!